FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar
The asset is indicated to treat paroxysmal nocturnal haemoglobinuria. Credit: MMC-Rodenbusch / Shutterstock. Samsung Bioepis has announced the approval of its EPYSQLI (eculizumab-aagh) biologics licence